Postmenopausal hyperandrogenism

References

• Markopoulos MC, Kassi E, Alexandraki KI, et al. Hyperandrogenism after menopause. Eur J Endocrinol. 2015;172(2):R79–R91.
   PubMed Web of Science ®Google Scholar
• Tutzer M, Winnykamien I, Davila Guardia J, et al. Hyperandrogenism in post-menopausal women: a diagnosis challenge. Gynecol Endocrinol. 2014;30(1):23–25.
   PubMed Web of Science ®Google Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95(5):2038–2049.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Lambrinoudaki I, Economou F, et al. Androgens associated with advanced glycation end-products in postmenopausal women. Menopause. 2010;17(6):1182–1187.
   PubMed Web of Science ®Google Scholar
• Rothman MS, Wierman ME. How should postmenopausal androgen excess be evaluated? Clin Endocrinol (Oxf). 2011;75(2):160–164.
   PubMed Web of Science ®Google Scholar
• Dolinko AV, Ginsburg ES. Hyperandrogenism in menopause: a case report and literature review. Fertil Res Pract. 2015;1:7.
   PubMedGoogle Scholar
• Goldman JM, Kapadia LJ. Virilization in a postmenopausal woman due to ovarian stromal hyperthecosis. Postgrad Med J. 1991;67(785):304–306.
   PubMed Web of Science ®Google Scholar
• Kim Y, Marjoniemi VM, Diamond T, et al. Androgenetic alopecia in a postmenopausal woman as a result of ovarian hyperthecosis. Australas J Dermatol. 2003;44(1):62–66.
   PubMedGoogle Scholar
• Krug E, Berga SL. Postmenopausal hyperthecosis: functional dysregulation of androgenesis in climacteric ovary. Obstet Gynecol. 2002;99(5 Pt 2):893–897.
   PubMed Web of Science ®Google Scholar
• Hofland M, Cosyns S, De Sutter P, et al. Leydig cell hyperplasia and Leydig cell tumour in postmenopausal women: report of two cases. Gynecol Endocrinol. 2013;29(3):213–215.
   PubMed Web of Science ®Google Scholar
• Nardo LG, Ray DW, Laing I, et al. Ovarian Leydig cell tumor in a peri-menopausal woman with severe hyperandrogenism and virilization. Gynecol Endocrinol. 2005;21(4):238–241.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Kitazawa S, Wakahashi S, et al. A case of virilizing brenner tumor in a postmenopausal woman with stromal androgenic activity. Int J Gynecol Pathol. 2006;25:230–232.
   PubMed Web of Science ®Google Scholar
• Goodarzi MO, Dawson DW, Li X, et al. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab. 2003;88(1):73–77.
   PubMed Web of Science ®Google Scholar
• Haring R, Hannemann A, John U, et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography–tandem mass spectrometry. J Clin Endocrinol Metab. 2012;97(2):408–415.
   PubMed Web of Science ®Google Scholar
• Elmlinger MW, Kuhnel W, Wormstall H, et al. Reference intervals for testosterone, androstenedione and SHBG levels in healthy females and males from birth until old age. Clin Lab. 2005;51(11–12):625–632.
   PubMed Web of Science ®Google Scholar
• Markopoulos MC, Rizos D, Valsamakis G, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab. 2011;96(3):623–631.
   PubMed Web of Science ®Google Scholar
• Winters SJ, Talbott E, Guzick DS, et al. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril. 2000;73(4):724–729.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Mamoojee Y, Ganguri M, Taylor N, et al. Clinical Case Seminar: postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis. Clin Endocrinol (Oxf). 2018;88(1):13–20.
   PubMed Web of Science ®Google Scholar
• Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(4):1105–1120.
   PubMed Web of Science ®Google Scholar
• Bode D, Seehusen DA, Baird D. Hirsutism in women. Am Fam Physician. 2012;85(4):373–380.
   PubMed Web of Science ®Google Scholar
• Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(4):1233–1257. PMID: 29522147.
   PubMed Web of Science ®Google Scholar
• Yance VRV, Marcondes JAM, Rocha MP, et al. Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies. Eur J Endocrinol. 2017;177(1):93–102.
   PubMed Web of Science ®Google Scholar
• Vaikkakara S, Al-Ozairi E, Lim E, et al. The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin. Gynecol Endocrinol. 2008;24(2):87–92.
   PubMed Web of Science ®Google Scholar
• Tritos NA, Cushing GW, Heatley G, et al. Clinical features and prognostic factors associated with adrenocortical carcinoma: Lahey Clinic Medical Center experience. Am Surg. 2000;66:73–79.
   PubMed Web of Science ®Google Scholar
• Barth JH, Jenkins M, Belchetz PE. Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women. Clin Endocrinol (Oxf). 1997;46(2):123–128.
   PubMed Web of Science ®Google Scholar
• Sarfati J, Bachelot A, Coussieu C, et al. Impact of clinical, hormonal, radiological, and immunohistochemical studies on the diagnosis of postmenopausal hyperandrogenism. Eur J Endocrinol. 2011;165(5):779–788.
   PubMed Web of Science ®Google Scholar
• Merz E, Miric-Tesanic D, Bahlmann F, et al. Sonographic size of uterus and ovaries in pre- and postmenopausal women. Ultrasound Obstet Gynecol. 1996;7(1):38–42.
   PubMed Web of Science ®Google Scholar
• Rousset P, Gompel A, Christin-Maitre S, et al. Ovarian hyperthecosis on grayscale and color Doppler ultrasound. Ultrasound Obstet Gynecol. 2008;32(5):694–699.
   PubMed Web of Science ®Google Scholar
• Shah D, Bansal S. Polycystic ovaries – beyond menopause. Climacteric. 2014;17(2):109–115.
   PubMed Web of Science ®Google Scholar
• Alsamarai S, Adams JM, Murphy MK, et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab. 2009;94(12):4961–4970.
   PubMed Web of Science ®Google Scholar
• Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril. 1988;50(2):197–212.
   PubMed Web of Science ®Google Scholar
• Kumar A, Woods KS, Bartolucci AA, et al. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2005;62(6):644–649.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Brannstrom M, Landin-Wilhelmsen K, et al. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab. 2011;96(7):2178–2185.
   PubMed Web of Science ®Google Scholar
• Kaltsas GA, Isidori AM, Besser G, Met al. Secondary forms of polycystic ovary syndrome. Trends Endocrinol Metab. 2004;15(5):204–210.
   PubMed Web of Science ®Google Scholar
• Moran C, Azziz R, Carmina E, et al. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstetr Gynecol. 2000;183(6):1468–1474.
   PubMed Web of Science ®Google Scholar
• Speiser PW, Serrat J, New MI, et al. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1992;75(6):1421–1424.
   PubMed Web of Science ®Google Scholar
• Kaltsas GA, Androulakis II, Tziveriotis K, et al. Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. Clin Endocrinol. 2007;67(6):917–922.
   PubMed Web of Science ®Google Scholar
• Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology. 2004;145(2):799–808.
   PubMed Web of Science ®Google Scholar
• Vademecum Gynecologic Oncology, edited by Paola Gehrig and Angeles Secord. 2009. CRC Press. ISBN 13:978-1-57059-705-3 (pbk)
   Google Scholar
• Gui T, Cao D, Shen K, et al. A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors. Gynecol Oncol. 2012;127(2):384–389.
   PubMed Web of Science ®Google Scholar
• Sigismondi C, Gadducci A, Lorusso D, et al. Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study. Gynecol Oncol. 2012;125(3):673–676.
   PubMed Web of Science ®Google Scholar
• Oliva E, Alvarez T, Young RH. Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol. 2005;29(2):143–156.
   PubMed Web of Science ®Google Scholar
• Sekkate S, Kairouani M, Serji B, et al. Ovarian granulosa cell tumors: a retrospective study of 27 cases and a review of the literature. World J Surg Oncol. 2013;11:142.
   PubMed Web of Science ®Google Scholar
• Kaltsas GA, Korbonits M, Isidori AM, et al. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing’s syndrome? Clin Endocrinol. 2000;53(4):493–500.
   PubMed Web of Science ®Google Scholar
• Nieman LK. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab. 2010;95(9):4106–4113.
   PubMed Web of Science ®Google Scholar
• Thompson GB, Young WF Jr. Adrenal incidentaloma. Curr Opin Oncol. 2003;15(1):84–90.
   PubMed Web of Science ®Google Scholar
• Moreno S, Montoya G, Armstrong J, et al. Profile and outcome of pure androgen-secreting adrenal tumors in women: experience of 21 cases. Surgery. 2004;136(6):1192–1198.
   PubMed Web of Science ®Google Scholar
• Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003;169(1):5–11.
   PubMed Web of Science ®Google Scholar
• Brown DL, Henrichsen TL, Clayton AC, et al. Ovarian stromal hyperthecosis: sonographic features and histologic associations. J Ultrasound Med. 2009; 28(5):587–593.
   PubMed Web of Science ®Google Scholar
• Nagamani M, Van Dinh T, Kelver ME. Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol. 1986;154(2):384–389.
   PubMed Web of Science ®Google Scholar
• Dennedy MC, Smith D, O'Shea D, et al. Investigation of patients with atypical or severe hyperandrogenaemia including androgen-secreting ovarian teratoma. Eur J Endocrinol. 2010;162(2):213–220.
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–3672.
   PubMed Web of Science ®Google Scholar
• Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90(7):3847–3853.
   PubMed Web of Science ®Google Scholar
• Gold EM. The Cushing syndromes: changing views of diagnosis and treatment. Ann Intern Med. 1979;90(5):829–844.
   PubMed Web of Science ®Google Scholar
• Aron DC, Findling JW, Tyrrell JB. Cushing’s disease. Endocrinol Metab Clin North Am. 1987;16(3):705–730.
   PubMedGoogle Scholar
• Kaltsas GA, Isidori AM, Kola BP, et al. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab. 2003;88(6):2634–2643.
   PubMed Web of Science ®Google Scholar
• Vollaard ES, van Beek AP, Verburg FA, et al. Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin. J Clin Endocrinol Metab. 2011;96(5):1197–1201.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–488.
   PubMed Web of Science ®Google Scholar
• Färkkilä A, Koskela S, Bryk S, et al. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors–a comparative study with inhibin B. Int J Cancer. 2015;137(7):1661–1671.
   PubMed Web of Science ®Google Scholar
• Giacobbe M, Mendes Pinto-Neto A, Simoes Costa-Paiva LH, et al. The usefulness of ovarian volume, antral follicle count and age as predictors of menopausal status. Climacteric. 2004;7(3):255–260.
   PubMed Web of Science ®Google Scholar
• Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601–610.
   PubMed Web of Science ®Google Scholar
• Chantler DJ, Gordon D, Millan D, et al. Use of cetrorelix in the investigation of testosterone excess in a postmenopausal woman. BMJ Case Rep. 2011;2011(apr21 1):bcr0120113730–4.
   PubMedGoogle Scholar
• Manieri C, Di Bisceglie C, Fornengo R, et al. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis. J Endocrinol Invest. 1998;21(2):128–132.
   PubMed Web of Science ®Google Scholar
• Stephens JW, Katz JR, McDermott N, et al. An unusual steroid-producing ovarian tumour: case report. Hum Reprod. 2002;17(6):1468–1471.
   PubMed Web of Science ®Google Scholar
• Pascale M-M, Pugeat M, Roberts M, et al. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. Clin Endocrinol (Oxf). 1994;41(5):571–576.
   PubMed Web of Science ®Google Scholar
• Moore EK, Padwick ML, Irvine LM. Novel management for virilisation in a postmenopausal woman. BJOG. 2013;120:239–240.
   Web of Science ®Google Scholar
• Pasquali R, Gambineri A. Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. Eur J Endocrinol. 2014;170(2):R75–R90.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189–2197.
   PubMed Web of Science ®Google Scholar
• Pelusi C, Forlani G, Zanotti L, et al. Nometabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours. Clin Endocrinol. 2013;78(4):533–538.
   PubMed Web of Science ®Google Scholar
• Key TJ, Appleby PN, Reeves GK, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011;105(5):709–722.
   PubMed Web of Science ®Google Scholar
• Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140(7):815–830.
   PubMed Web of Science ®Google Scholar
• Alpanes M, Gonzalez-Casbas JM, Sanchez J, Pian H, Escobar-Morreale HF. Management of postmenopausal virilization. J Clin Endocrinol Metab. 2012;97(8):2584–2588.
   PubMed Web of Science ®Google Scholar